Has Pallavi Joshi received payments from drug or device companies?

Yes. Drug and device makers reported $2,006 in general payments to Pallavi Joshi across 22 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pallavi Joshi did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pallavi Joshi come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pallavi Joshi

Psychiatry · Phoenix, AZNPI 1750765442

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 35.0% of the total. Reporting peaked in 2022 at $688 and has fallen 86.5% since, to $93 in 2025.

$2,006in general payments, 2019–2025

Across 22 payments — averaging $91.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teva Pharmaceuticals USA, Inc.$701
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$475
Neurocrine Biosciences, Inc.$335
Roche Diagnostics Corporation$228
Alkermes, Inc.$94
Otsuka Pharmaceutical Development & Commercialization, Inc.$64
plus $107 from 3 others

$60,223in research payments, 2019–2025

Across 5 payments — averaging $12,045 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$60K
Merck$35

What the payments were for

Food & beverage$2,006100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teva Pharmaceuticals USA, Inc.	7	$701
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$475
Neurocrine Biosciences, Inc.	3	$335
Roche Diagnostics Corporation	2	$228
Alkermes, Inc.	1	$94
Otsuka Pharmaceutical Development & Commercialization, Inc.	2	$64
Lilly USA, LLC	1	$59
Supernus Pharmaceuticals, Inc.	1	$32
Otsuka America Pharmaceutical, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,006 in reported general payments places this provider in the 80th percentile of 573 psychiatry providers in Arizona.

See all psychiatry providers in Arizona →

Medicare billing

Part B allowed, 2024

$39,672

Medicare patients

152

Services billed

263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Rivastigmine	59	$13,341
Memantine Hcl	175	$8,227
Sertraline Hcl	37	$4,388
Donepezil Hcl	265	$3,562
Escitalopram Oxalate	142	$2,413
RivastigmineRivastigmine Tartrate	30	$2,233
Aripiprazole	42	$2,169
Quetiapine Fumarate	79	$1,449
Galantamine ErGalantamine Hbr	14	$1,446
Bupropion XlBupropion Hcl	38	$1,081
Mirtazapine	18	$662
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	14	$433
Fluoxetine Hcl	40	$323
Trazodone Hcl	17	$147

Paid to pharmacies, not to this prescriber.

Other psychiatry in Phoenix

Jason CaplanPhoenix$999K
Thomas GazdaPhoenix$714K
Monica BenavidezPhoenix$435K
Eric ReimanPhoenix$157K
Padma AkingPhoenix$44K
Ahmed ElmaadawiPhoenix$32K
Amnon KahanePhoenix$18K
Aaron ClayPhoenix$14K
Joel ParkerPhoenix$11K
Ivan EngelPhoenix$10K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →